SAGE vs. VERA, IOVA, PRAX, GLPG, WVE, APGE, EVO, IRON, ARQT, and AMPH
Should you be buying Sage Therapeutics stock or one of its competitors? The main competitors of Sage Therapeutics include Vera Therapeutics (VERA), Iovance Biotherapeutics (IOVA), Praxis Precision Medicines (PRAX), Galapagos (GLPG), Wave Life Sciences (WVE), Apogee Therapeutics (APGE), Evotec (EVO), Disc Medicine (IRON), Arcutis Biotherapeutics (ARQT), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical products" industry.
Sage Therapeutics vs.
Sage Therapeutics (NASDAQ:SAGE) and Vera Therapeutics (NASDAQ:VERA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, community ranking, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.
In the previous week, Sage Therapeutics had 5 more articles in the media than Vera Therapeutics. MarketBeat recorded 12 mentions for Sage Therapeutics and 7 mentions for Vera Therapeutics. Sage Therapeutics' average media sentiment score of 0.81 beat Vera Therapeutics' score of 0.16 indicating that Sage Therapeutics is being referred to more favorably in the media.
Vera Therapeutics has lower revenue, but higher earnings than Sage Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.
99.2% of Sage Therapeutics shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 5.5% of Sage Therapeutics shares are owned by company insiders. Comparatively, 21.7% of Vera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Vera Therapeutics has a net margin of 0.00% compared to Sage Therapeutics' net margin of -971.50%. Vera Therapeutics' return on equity of -50.13% beat Sage Therapeutics' return on equity.
Sage Therapeutics has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.
Sage Therapeutics presently has a consensus target price of $9.65, suggesting a potential upside of 32.24%. Vera Therapeutics has a consensus target price of $65.44, suggesting a potential upside of 127.16%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Vera Therapeutics is more favorable than Sage Therapeutics.
Sage Therapeutics received 594 more outperform votes than Vera Therapeutics when rated by MarketBeat users. Likewise, 65.19% of users gave Sage Therapeutics an outperform vote while only 65.00% of users gave Vera Therapeutics an outperform vote.
Summary
Vera Therapeutics beats Sage Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Sage Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sage Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SAGE) was last updated on 2/21/2025 by MarketBeat.com Staff
